CoverageForm 410-K10-Q8-K13D13G13F

IIN · Intricon Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Income Statement

Line itemFY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Revenue$125.21M$102.77M$113.49M$68.98M$68.01M$67.09M
Cost of Revenue$93.82M$76.60M$82.51M$79.30M$61.82M$50.94M
Gross Profit$31.39M$26.18M$30.99M$37.16M$26.49M$17.07M
R&D$5.32M$5.25M$3.83M$4.67M$4.46M$4.69M
SG&A$16.58M$15.01M$13.93M$13.01M$10.34M$9.15M
Total Operating Expenses$30.90M$29.25M$33.03M$30.05M$24.24M$18.67M
D&A$5.54M$4.62M$3.28M$2.94M$2.19M$2.04M
Operating Income$487.0K($3.08M)($2.04M)$7.11M$2.25M($1.60M)
Interest Expense---$553.0K$369.0K$461.0K
Income Tax$135.0K$61.0K$201.0K$484.0K$8.0K$217.0K
Net Income($106.0K)($2.52M)($3.78M)$5.55M$1.80M($4.59M)
EPS - Basic($0.01)($0.28)($0.43)$0.73$0.26($0.71)
EPS - Diluted($0.01)($0.28)($0.43)$0.64$0.25($0.71)

Balance Sheet

Line itemFY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Cash & Equivalents$5.58M$8.61M$1.26M$979.0K$328.0K$217.0K
Accounts Receivable$8.26M$10.12M$8.99M$11.48M$9.05M$7.29M
Inventory$24.46M$19.51M$16.38M$18.98M$15.40M$12.34M
Accounts Payable$9.40M$8.67M$9.88M$13.19M$10.42M$6.72M
Current Assets$74.38M$69.27M$70.28M$84.54M$27.01M$21.97M
Total Assets$122.46M$121.30M$113.59M$115.25M$53.18M$43.76M
Current Liabilities$20.21M$18.66M$16.93M$21.65M$18.80M$13.52M
Long-term Debt---$9.32M$9.28M$7.93M
Total Liabilities$28.71M$30.10M$23.10M$23.27M$32.52M$24.75M
Stockholders' Equity$93.66M$91.16M$90.75M$92.23M$20.92M$18.56M
Retained Earnings($6.92M)($6.81M)($4.29M)($509.0K)($6.83M)($8.63M)

Cash Flow

Line itemFY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Operating Cash Flow$438.0K$5.62M$1.47M($405.0K)$4.23M($405.0K)
Investing Cash Flow($2.22M)($3.50M)($242.0K)($2.30M)($2.30M)($958.0K)
Financing Cash Flow($1.15M)($1.99M)($109.0K)$3.51M$3.53M($1.94M)
CapEx$2.50M$3.63M$4.59M$5.51M$2.31M$1.77M
Free Cash Flow($2.07M)$1.99M($3.12M)($5.91M)$1.92M($2.17M)

Ratios

MetricFY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Profitability
Gross margin25.1%25.5%27.3%53.9%39.0%25.4%
Operating margin0.4%-3.0%-1.8%10.3%3.3%-2.4%
EBITDA margin4.8%1.5%1.1%14.6%6.5%0.7%
Net margin-0.1%-2.5%-3.3%8.0%2.6%-6.8%
Free cash flow margin-1.7%1.9%-2.8%-8.6%2.8%-3.2%
FCF / Net income19.49-0.790.83-1.071.060.47
R&D / Revenue4.2%5.1%3.4%6.8%6.6%7.0%
SG&A / Revenue13.2%14.6%12.3%18.9%15.2%13.6%
Effective tax rate465.5%--8.0%0.4%-
Return on assets-0.1%-2.1%-3.3%4.8%3.4%-10.5%
Return on equity-0.1%-2.8%-4.2%6.0%8.6%-24.7%
Return on invested capital---6.4%7.4%-4.8%
Liquidity
Current ratio3.683.714.153.911.441.63
Quick ratio2.472.673.183.030.620.71
Cash ratio0.280.460.070.050.020.02
Leverage
Debt / Equity---0.100.440.43
Debt / Assets---0.080.170.18
Debt / EBITDA---0.932.0918.06
Interest coverage---12.9x6.1x-3.5x
Equity multiplier1.311.331.251.252.542.36
Liabilities / Assets0.230.250.200.200.610.57
Efficiency
Asset turnover1.020.851.000.601.281.53
Inventory turnover3.843.935.044.184.024.13
Days sales outstanding24d36d29d61d49d40d
Days inventory outstanding95d93d72d87d91d88d
Days payable outstanding37d41d44d61d62d48d
Cash conversion cycle83d88d58d87d78d80d
Valuation
P / E------
P / B------
P / S------
EV / EBITDA------
Growth
Revenue growth (YoY)21.8%-9.4%64.5%1.4%1.4%26.7%
Revenue CAGR (3y)22.0%14.8%19.2%9.2%4.3%8.8%
Revenue CAGR (5y)13.3%14.2%13.6%5.8%3.0%5.4%
Gross profit growth (YoY)19.9%-15.5%-16.6%40.3%55.2%-10.2%
Operating income growth (YoY)--50.7%-216.6%--
Net income growth (YoY)95.8%33.2%-207.8%--
EPS growth (YoY)96.4%34.9%-156.0%--
EPS CAGR (3y)---21.1%-12.3%-
EPS CAGR (5y)----15.8%-
FCF growth (YoY)--47.2%--33.6%
FCF CAGR (5y)----47.8%-
Book value growth (YoY)2.7%0.5%-1.6%340.9%12.7%-1.8%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2021-12-31.

Product / service

$119.85M total
Diabetes$69.73M · 58.2%
Interventional Catheters$14.57M · 12.2%
Hearing Health Legacy Oem$10.85M · 9.1%
Medical Biotelemetry Other$8.72M · 7.3%
Hearing Health Value Based ITEC$8.05M · 6.7%
Professional Audio Communications$4.44M · 3.7%
Hearing Health Value Based DTEC$3.48M · 2.9%

Geographic

$125.21M total
US$92.92M · 74.2%
All Other Countries$13.17M · 10.5%
Asia$12.55M · 10.0%
Europe$6.56M · 5.2%

Stability scores

Altman Z′

FY 2021 · bankruptcy risk

2.67
Grey zone

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2021 · 9-point quality

4/9
Neutral
  • Net income positive
  • Operating cash flow positive
  • ROA improved YoY
  • Cash flow > net income
  • -Long-term debt decreased
  • Current ratio improved
  • No share dilution
  • Gross margin improved
  • Asset turnover improved

Peer comparison

Same SIC group: Electronic Components & Accessories

CompanyRevenue (last FY)Net marginROE
OLED$650.61M37.2%13.7%
HUBB$5.84B15.2%23.1%
MRCY$912.02M-4.2%-2.6%
VSH$3.07B-0.3%-0.4%
SNPO---

Comparing INTRICON CORP against the 5 most active filers in the same SIC group.